|Videos|June 27, 2023

DIA 2023: Tamei Elliott Discusses Changes to the Role of Diversity in Clinical Trials

In an interview at the DIA Global Annual Meeting with Nicholas Saraceno, Tamei Elliott,Senior Manager, Scientific Programs, Drug Information Association, discusses changes to the role of diversity in clinical trials in regard to scientific programing.

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Related Content

A survey of 300 clinical operations executives conducted last year by Frost & Sullivan and sponsored by IQVIA found that the manual effort required to connect siloed systems and processes is the top challenge in clinical trial financials. Credit: Stock.Adobe.com/photon_photo.

From Doing to Reviewing: How a Connected Ecosystem Streamlines Clinical Trial Finance

ByRajesh Patel,Zahiah (Zee Zee) Gueddar

August 26th 2026

Beyond Compliance: AJNA BioSciences' Joel Stanley on Bringing Botanical Medicine Through the FDA Pathway

ByOtis Johnson, PhD, MPA,Joel Stanley,Andy Studna, Senior Editor

August 26th 2026

Where AI Is Delivering Real Value in Clinical Trial Payments Right Now

ByPatrick Mizer,Andy Studna, Senior Editor

August 26th 2026

ACT Brief: Payment Infrastructure and Site Cash, Inspection Readiness Throughout Execution, and First Hemolytic Anemia Therapy

ByAndy Studna, Senior Editor

August 26th 2026

Inspection Readiness Is Not a Pre-Inspection Activity, It's an Execution Design Condition

ByElizabeth Walsh, PMP, ACRP-CP

August 25th 2026

Trending on Applied Clinical Trials Online

Beyond Compliance: AJNA BioSciences' Joel Stanley on Bringing Botanical Medicine Through the FDA Pathway

Where AI Is Delivering Real Value in Clinical Trial Payments Right Now

From Doing to Reviewing: How a Connected Ecosystem Streamlines Clinical Trial Finance

Connected Trial Execution: Why Integrating IRT, eCOA and Clinical Supply Matters More Than Ever

ACT Brief: Payment Performance as Operational Brand, Speed and Discipline in Biotech Development Strategy, and Non-GLP-1 Obesity Candidate Licensing